#kidney

It’s the NIH’s first large-scale clinical trial on the subject. Plus: Meet organ transplant advocate Mo Murray [VIDEO].

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.

Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.

HIV-positive to HIV-positive transplants are now possible for people living with the virus.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Organ transplants between HIV-positive people have taken place since 2016—but until now, the donors were deceased.

Among the hep C population, other factors associated with chronic kidney disease include being older and having diabetes or HIV.

The single-tablet regimen contains ViiV’s Tivicay (dolutegravir) and Janssen’s Edurant (rilpivirine).

A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.

Worldwide, kidneys from three deceased HIV-positive donors have been transplanted into six people living with the virus.

Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.